FDA Hearing Backs Psychedelic Therapy Potential, Stresses Safety

The U.S. Food and Drug Administration held a public hearing on Monday to gather feedback on the potential future use of psychedelic drugs in supervised therapeutic settings, marking a significant step in the federal government's push to accelerate research into treatments for severe mental health conditions. The four-hour session at the FDA's White Oak campus in Silver Spring, Maryland, drew approximately 80 speakers, including doctors, veterans, therapists, and researchers, who overwhelmingly supported the therapeutic potential of psychedelics while emphasizing the need for robust safety standards. Most speakers highlighted the efficacy of psychedelic-assisted therapy for conditions like major depressive disorder and post-traumatic stress disorder (PTSD). Marine Corps veteran Eric Jansen credited his survival to two overseas psychedelic treatments using ayahuasca and ibogaine, urging that veterans should not be forced to leave the country to access such care. Nurse Tina Braddock told the panel that nurses are already licensed and trained to help make treatments safe and accessible.